CIRM Funded Clinical Trials

Progenitor Cells Secreting GDNF for the Treatment of ALS


Clive Svendsen
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
18
ClinicalTrials.gov ID:

CIRM Awards Funding This Trial

Investigator:
CIRM Grant:
Award Value:
$17,842,617
Investigator:
CIRM Grant:
Award Value:
$6,154,067
Details: 

ALS is a devastating neurodegenerative disease with no cure that specifically affect a patient's motor neurons.  This cell therapy intends to support sick motor neurons via astrocyte replacement and pro-survival growth factors. Allogeneic neural stem cells, genetically modified to express GDNF, are injected into the patient spinal cord where they develop into astrocytes. 

Design: 

Dose escalation. Open label.

Goal: 

Safety. Dosing. Efficacy - Lower limb strength

Status: 

Actively recruiting.